#ShinNipponBiomedical

Consolidated net sales for the third quarter of FY2026 amounted to JPY 21,195 million (4.7% decrease YoY), operating income was JPY 1,027 million (45.7% decrease YoY), and net income attributable to owners of parent for the quarter was JPY 2,270 million (29.2% decrease YoY).

The full-year sales forecast for the fiscal year ending March 2026 has been revised to 306.98 billion yen (7.7% decrease from previous forecast), operating income to 2.6 billion yen (26.8% decrease), and ordinary income to 5.353 billion yen (9.7% decrease).

Cumulative Q3 sales for FY2026 were 21.19 billion yen, a 4.7% decrease YoY, with operating income of 1.02 billion yen, down 46.1% YoY. The full-year earnings forecast was revised downward, projecting sales of 30.69 billion yen and operating income of 2.60 billion yen.